

Lawrence Berkeley National Laboratory

Biological Systems & Engineering

Title

A simple method to control glycolytic flux for the design of an optimal cell factory

Permalink

<https://escholarship.org/uc/item/8zm4j4m2>

Journal

Biotechnology for Biofuels and Bioproducts, 10(1)

ISSN

2731-3654

Authors

Lim, Jae Hyung
Jung, Gyoo Yeol

Publication Date

2017-12-01

DOI

10.1186/s13068-017-0847-4

Peer reviewed

RESEARCH

Open Access



A simple method to control glycolytic flux for the design of an optimal cell factory

Jae Hyung Lim¹ and Gyoo Yeol Jung^{1,2*}

Abstract

Background: A microbial cell factory with high yield and productivity are prerequisites for an economically feasible bio-based chemical industry. However, cell factories that show a kinetic imbalance between glycolysis and product formation pathways are not optimal. Glycolysis activity is highly robust for survival in nature, but is not optimized for chemical production.

Results: Here, we propose a novel approach to balance glycolytic activity with the product formation capacity by precisely controlling expression level of *ptsG* (encoded glucose transporter) through UTR engineering. For various heterologous pathways with different maximum production rates, e.g., *n*-butanol, butyrate, and 2,3-butanediol, glycolytic fluxes could be successfully modulated to maximize yield and productivity, while minimizing by-product formation in *Escherichia coli*.

Conclusions: These results support the application of this simple method to explore the maximum yield and productivity when designing optimal cell factories for value-added products in the fields of metabolic engineering and synthetic biology.

Keywords: Glycolytic flux, *n*-Butanol, 2,3-Butanediol, Butyrate, UTR engineering, PTS

Background

Optimal microbial cell factories are essential to develop economically feasible production processes for various value-added chemicals from renewable biomass at an industrial scale [1]. Therefore, the design of cell factories in the fields of metabolic engineering and synthetic biology aims to maximize cellular performance in terms of yield and productivity. This optimization is particularly important for high-volume (and low-value) bulk chemicals and biofuels [2], e.g., *n*-butanol (an alternative to gasoline) [3], butyrate (chemical feedstock for plastics) [4], and 2,3-butanediol (for rubbers) [5].


In general, cell factories can be simplified into two parts: a carbon utilization pathway, such as glycolysis, and a product formation pathway (Fig. 1). Traditionally, research in this field has focused on the product-forming

pathways of interest. Yield can be enhanced by rerouting the carbon flux toward the target product by eliminating endogenous side reactions, and productivity can be improved by increasing the catalytic activity of kinetic bottlenecks in the product formation pathway [6–8]. However, we additionally speculated that the kinetic imbalance between glycolysis and product formation pathways should be considered in the design principle for optimal cell factories to maximize yield and productivity. When the maximum catalytic activity of the engineered pathway, i.e., the capacity of the product formation pathway, is lower than the glycolytic activity, additional carbon inputs can be wasted as by-products and the yield is consequently reduced (Fig. 1, Product A). In contrast, if the product formation capacity exceeds the glycolytic flux, glycolytic activity can be regarded as the rate-limiting step and increases in activity are necessary to improve productivity (Fig. 1, Product B). Pyruvate, for example, is a critical intermediate between sugar uptake and product formation as a final metabolite of glycolysis in almost all organisms [9]. Excess pyruvate, i.e., quantities that

*Correspondence: gyjung@postech.ac.kr

¹ Department of Chemical Engineering, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Korea

Full list of author information is available at the end of the article



exceed the requirement for product formation, is inevitably secreted from the cell [10, 11], causing a substantial reduction in yield, whereas a lack of pyruvate limits the product formation rate, i.e., reduces productivity (Fig. 1). Taken together, a balance between glycolysis and product formation is required to construct a microbial cell factory with the maximum performance and this can be achieved via the precise control of glycolysis to maintain a balance with the capacity of the product formation pathway [12, 13].

However, methods to control the glycolytic flux are not well-studied owing to the robustness of native glycolytic activity, which is mediated by complex regulatory systems at many levels, including transcription, translation, and the allosteric control of enzymes [14]. Therefore, we focused on the carbon uptake system for the artificial control of carbon influx and simultaneously attempted to

detour innate cellular regulatory mechanisms. There are several routes to start glycolysis in bacteria. For example, the phosphoenolpyruvate (PEP)-dependent sugar phosphotransferase system (PTS) that predominantly participates in both the transportation and phosphorylation of glucose. Alternatively, glucose can be internalized by a galactose transporter (GalP or MglABC) and subsequently phosphorylated by hexokinase to enter glycolysis. As such alternative pathways enable to decouple glucose transportation and PEP-dependent phosphorylation, and therefore the pathways were previously exploited to increase precursor availability, such as PEP and free glucose, for the production of aromatic amino acids [15, 16] and gluconic acid [17, 18], respectively. Strikingly, however, the PTS is the most efficient system in terms of energetic costs and kinetic parameters for glucose transportation among the routes [19]. The group translocation

system is composed of non-sugar-specific soluble proteins: the phosphohistidine carrier protein (HPr) and the Enzyme I (EI) component (encoded by *ptsH* and *ptsI*, respectively), the glucose-specific cytoplasmic enzyme EIIA (EIIA^{Glc}, encoded by *crr*), and the membrane-bound glucose-specific enzyme IICB (EIIICB^{Glc}, encoded by dicistronic *ptsG*) [19, 20]. Moreover, PTS is primarily responsible for the control of glucose uptake in response to overflow glycolytic flux (for example, the accumulation of glucose-6-phosphate) via the post-transcriptional repression of *ptsG* as the initial step in glucose import [21, 22]. Previous studies revealed that *Escherichia coli* small RNA SgrS is induced under glucose phosphate stress and it causes the translational repression and the RNaseE-dependent rapid degradation of the *ptsG* mRNA [23] by binding to the 5'-end of mRNA [24, 25]. More recent work characterized a minimal base-pairing region between SgrS and *ptsG* mRNA that 14nt base-pairing region including Shine–Dalgarno (SD) sequence of the target mRNA is sufficient to inhibit *ptsG* translation (Fig. 2) [26].

In this study, we examined the potential use of *ptsG* as a simple method to control the overall glycolytic flux simply by designing a synthetic 5'-untranslated region (UTR). UTR engineering is a suitable approach for controlling expression of target genes as well as for eliminating the unpredictable regulatory elements within the metabolic pathway [27]. Furthermore, we demonstrated the importance of rebalancing glycolytic flux depending on the efficiency of product formation pathways using recombinant *E. coli* strains producing *n*-butanol, butyrate, or 2,3-butanediol as model cell factories. Our approach enables the maximization of both yield and productivity in the construction of microbial cell factories by simply optimizing glycolytic flux; accordingly, it has broad applications for the cost-effective production of various chemicals and fuels.

```

SgrS 3'-GGUUAUGAGUCAGUGUGU-ACUACG-UCC-5'
      * * * * *
WT 5'-CCCATACTCAGGAGCACTCTCAATT-ATG-3'
UTR1 5'-ATAITGAGAAGGACATCTCC TCGATAATG-3'
UTR2 5'-ATAITGAGAAGGAGATATCTCAATA-ATG-3'
UTR3 5'-ATAITGAGAAGGAGTTATCTCGATA-ATG-3'
UTR4 5'-ATAACGAGTAGGAGTTTCTCGATA--ATG-3'
UTR5 5'-ACATTCACAAGGAGACGTCACAAATCATG-3'
  
```

Fig. 2 Redesign of the 5'-UTR for *ptsG* based on base-pairs between SgrS and *ptsG*. The asterisks indicate the predicted base-pairing region of SgrS required for the translational repression of *ptsG* mRNA [24]. In particular, the minimal base-pairs for SgrS action for effective translational inhibition are shown in bold [26, 48]. The italic letters represent the Shine–Dalgarno (SD) sequence and the initiation codon for *ptsG*. The changed nucleotides with respect to the wild-type sequence of the *ptsG* UTR are underlined

Methods

Reagents, bacterial strains, and plasmids

A list of *E. coli* bacterial strains and plasmids used in this study is presented in Additional file 1: Table S1. Oligonucleotides used in this study were synthesized by Macrogen (Daejeon, Korea) and are listed in Additional file 1: Table S2. The *rpsL-neo* template DNA was obtained using the Counter-selection BAC Modification Kit (Gene Bridges, Heidelberg, Germany). Phusion DNA Polymerase and restriction endonuclease were supplied by New England Biolabs (Ipswich, MA, USA), and T4 DNA ligase was purchased from Takara Bio Inc. (Shiga, Japan). Genomic DNA and propagated plasmids were prepared using a GeneAll Exgene™ Cell SV Kit (GeneAll Biotechnology, Seoul, Korea) and an AccuPrep Nano-Plus Plasmid Mini Extraction Kit (Bioneer, Daejeon, Korea), respectively. Restriction enzyme-digested products were purified using a GeneAll Expin™ Gel SV Kit (GeneAll Biotechnology). All cell culture reagents were purchased from BD Biosciences (Sparks, MD, USA), and all other chemicals used in this study were purchased from Sigma (St. Louis, MO, USA), unless otherwise indicated.

Chromosomal modifications, including deletions and substitutions of the 5'-UTR of *ptsG*, were performed using the Red recombination system. Specifically, the knock-out mutant of *ptsG* was constructed using the Red recombination system with pKD46 and pCP20 [28, 29]. To increase the efficiency of homologous recombination, disruption cassettes with different priming sites (pFRT 4) were cloned and amplified using *ptsG_del4_F* and *ptsG_del4_R*, as described in our previous studies [3, 4]. In addition, the replacement of the native UTR of *ptsG* was performed using the scar-less recombineering method [30] with Red recombination and the *rpsL-neo* counterselection system according to the manufacturer's instructions. For example, a mutation within the *rpsL* gene that confers a streptomycin-resistant phenotype was introduced using *rpsL*-A128G-oligo. The resulting JHL163 (*rpsL*^{*A128G}) strain was subjected to the insertion of a *rpsL-neo* cassette upstream of the *ptsG* structural gene, exhibiting recessive sensitivity to streptomycin in a merodiploid (JHL110). Finally, oligo recombination using [*ptsG*_UTR(1 to 5)_oligo] that had distinctly redesigned 5'-UTR sequences based on UTR Designer (http://sbi.postech.ac.kr/utr_designer) [31] resulted in the *ptsG* UTR variants, UTR1, 2, 3, 4, and 5, without gaps (Fig. 2). The other strains were constructed in the same manner.

Media and growth conditions

Physiological analyses were conducted as follows: wild-type *E. coli* was aerobically cultivated using M9 medium (6.78 g of Na₂HPO₄, 3 g of KH₂PO₄, 1 g of NH₄Cl, 0.5 g of NaCl, 2 mL of 1 M MgSO₄, and 0.1 mL of 1 M

CaCl₂/L) supplemented with 40 g/L glucose [32]. Streptomycin (25 µg/mL) was used to determine the genotype of rpsL*_{A128G}. Overnight culture broths in LB medium were inoculated at approximately 1% into M9 culture medium and cultivated until reaching an optical density at 600 nm (OD₆₀₀) of ~0.8. The culture broths were inoculated at a final OD₆₀₀ of 0.05 in 25 mL of M9 medium in a 300-mL flask and incubated at 37 °C with shaking (250 rpm). The production of *n*-butanol was assayed using Terrific Broth (TB; 12 g of tryptone, 24 g of yeast extract, 2.31 g of KH₂PO₄, 12.54 g of K₂HPO₄, and 4 mL of glycerol per liter) supplemented with 25 g/L glucose. Multiple plasmids were maintained using 25 µg/mL spectinomycin and 15 µg/mL kanamycin (pCDF-BuOH and pCOLA-F5). Rubber-sealed, 60-mL serum bottles were used for anaerobic cultures using an anaerobic chamber (Coy Laboratories, Ann Arbor, MI, USA). Overnight culture broths in LB medium were inoculated into 20 mL of fresh TB medium at a final OD₆₀₀ of 0.05 and incubated anaerobically at 37 °C in a rotary shaker (250 rpm) [3]. The production of butyric acid was assayed using Terrific Broth (TB; 12 g of tryptone, 24 g of yeast extract, 2.31 g of KH₂PO₄, 12.54 g of K₂HPO₄, excluding glycerol) supplemented with 10 g/L glucose. The plasmid (pBASP) was maintained by including 34 µg/mL chloramphenicol. Rubber-sealed, 60-mL serum bottles were used for anaerobic cultures using an anaerobic chamber (Coy Laboratories). Overnight culture broths in LB medium were inoculated into 20 mL of fresh TB medium at a final OD₆₀₀ of 0.05 and incubated anaerobically at 37 °C in a rotary shaker (250 rpm) [4]. The production of 2,3-butanediol was tested using M9 medium (6.78 g of Na₂HPO₄, 3 g of KH₂PO₄, 1 g of NH₄Cl, 0.5 g of NaCl, 2 mL of 1 M MgSO₄, and 0.1 mL of 1 M CaCl₂/L) supplemented with 40 g/L glucose and 5 g/L yeast extract. The plasmid (pZS-budABC) was maintained by including 30 µg/mL kanamycin. Overnight culture broths in culture medium were inoculated into 100 mL of modified M9 medium at a final OD₆₀₀ of 0.05 and incubated at 37 °C in a rotary shaker (180 rpm) under micro-aerobic condition. The anhydrotetracycline was added to a final concentration of 100 ng/mL when the OD₆₀₀ reached approximately 0.5 [5]. Theoretical yield was determined on the basis of pathway stoichiometry, e.g., 1 mol of *n*-butanol per 1 mol of glucose.

Analytical methods

The concentrations of glucose, organic acids, and alcohols were determined using high-performance liquid chromatography (UltiMate 3000 Analytical HPLC System; Dionex, Sunnyvale, CA, USA) with an Aminex HPX-87H Column (Bio-Rad Laboratories, Richmond, CA, USA) using 5 mM H₂SO₄ as the mobile phase. The 2,3-butanediol samples were analyzed at a flow rate of

0.5 mL/min at 65 °C and otherwise a flow rate of 0.6 mL/min at 14 °C was used to quantify metabolites. The signal was monitored using a UV-Vis diode array detector (at 210 nm) and a Shodex RI-101 detector (Shodex, Klokkefaldet, Denmark).

Glucose uptake rate


The specific glucose uptake rate was determined as growth rate divided by biomass yield during exponential growth as previously described [33]. One OD₆₀₀ unit corresponds to 0.25 g dry cell weight (DCW)/L [34]. Instead, glucose consumption rate, determined as the analytic data from HPLC during the initial exponential phase, was represented for the production systems as the components in the TB medium also contributed to biomass yield.

Results

Tuning glycolytic activity through UTR engineering of *ptsG*

We initially redesigned five 5'-UTR variants to control *ptsG* activity as well as to deregulate translational repression [27] by the bacterial small RNA SgrS (which mediates phosphosugar stress responses) by modifying the minimal base-pairing region essential for SgrS action [26] (Fig. 2). As shown in Fig. 3b, seven strains with UTR variants, including positive (UTR_{WT}) and negative ($\Delta ptsG$) control strains, showed the various specific glucose uptake rates that were highly correlated with specific growth rates ($R^2 = 0.89$) in the minimal medium. These results agree with previous continuous culture data indicating that the specific glucose uptake rate increases linearly as a function of the dilution or growth rate [33, 35]. Moreover, differences in the glucose consumption rate were also related to the accumulation of acetate ($R^2 = 0.88$) and pyruvate ($R^2 = 0.77$) (Fig. 3a, c, d). As the secretion of acetate and pyruvate is generally considered to result from a higher carbon flux than the flux through the TCA cycle, which is required for both biosynthesis and energy production (Fig. 3a) [10, 36], the accumulation of acetate and pyruvate as natural by-products in wild-type *E. coli* collectively represents glycolytic activity. Consequently, our results show that UTR engineering of *ptsG* could successfully modulate overall PTS activity (represented as the glucose uptake rate) and glycolytic flux.

Interestingly, the redesign of the upstream region of *ptsG* enabled a higher specific glucose uptake rate (+20.8%), probably due to the deregulation of SgrS action, and subsequently led to a higher growth rate (+7.3%) and higher accumulation of acetate (+13.9%) and pyruvate (+11.0%) than those of the parental strain (Fig. 3b–d). These results indicate that the glucose transporter (encoded by *ptsG*) can amplify glycolytic flux as a




preliminary rate-determining step, even in the presence of complex regulatory mechanisms for other glycolytic enzymes [14].

Leak-free pathway engineering to improve *n*-butanol cell factory yield

The *n*-butanol synthetic pathway was selected as an example in which glycolytic activity was higher than product formation under anaerobic condition. Previously, many studies have attempted to optimize the *n*-butanol production pathway, but substantial levels of pyruvate accumulated as a by-product in the medium, indicating the *n*-butanol synthesis pathways are still

inefficient [3, 37, 38]. Therefore, in this case, tuning down of glycolytic flux is an effective way to minimize wasteful pyruvate production, which decreases yield (Fig. 4a).

We used an approach that we termed leak-free pathway engineering to improve the yield of the *n*-butanol cell factory. Seven *ptsG* UTR variants, including the native sequence (JHL 178–183), were engineered using *n*-butanol-producing *E. coli* JHL 59 (Δ *atoDA* Δ *adhE* Δ *ldhA* Δ *paa*FGH Δ *frd*ABCD Δ *pta* P_{*atoB*}::BBa_J23100 P_{*lpd*}::BBa_J23100 *lpd*(G1060A) P_{*aceEF*}::BBa_J23100) as the parental strain [3]. After a 24-h fermentation period, each variant showed different physiological results in terms of the accumulation of biomass, *n*-butanol, and



pyruvate as well as glucose consumption (Fig. 4b). Along with the decrease in the glucose consumption rate, 99% of pyruvate secretion was successfully eliminated, from 43.92 mM in UTR5 (JHL179) to 0.50 mM in $\Delta ptsG$ (JHL184), by glycolytic flux modulation, and there was a strong correlation between pyruvate secretion and the glucose consumption rate ($R^2 = 0.98$) (Fig. 4c). The final

titer of *n*-butanol decreased from 69.88 mM (UTR_{WT}, JHL178) to 54.54 mM ($\Delta ptsG$, JHL184) (Fig. 4b). In addition, the specific growth rate showed strong correlations between the glucose consumption rate ($R^2 = 0.93$) and the specific glucose uptake rate ($R^2 = 0.94$), even in rich TB medium (Additional file 1: Figures S1, S2, respectively). These results indicate that controlling the *ptsG*

expression level through UTR engineering could successfully modulate the glycolytic flux of the engineered strain, even under anaerobic conditions.

To evaluate cellular performance in *n*-butanol production, yield and productivity were examined (Fig. 4d). Notably, *n*-butanol yield increased as glycolytic flux decreased, which was attributed to a reduction in pyruvate leakage (Fig. 4c), but only slight changes in productivity were observed. This clearly shows that reducing glycolytic flux by modifying the glucose uptake rate had a greater influence on pyruvate secretion than *n*-butanol production. Among the tested variants, the JHL181 strain with the UTR3 variant indicated the optimal glycolytic flux for the best trade-off between yield and productivity as it showed 84% of the theoretical maximum yield by a 20% improvement (0.84 mol butanol/mol glucose) compared to the parental strain, but exhibited negligible changes in productivity (2.90 mM butanol L/h for UTR3 vs. 2.91 mM butanol L/h for UTR_{WT}) (Fig. 4d). Under the level of UTR3, however, *n*-butanol productivity decreased as a function of the glucose uptake rate, even though the yield increased to 93% of the theoretical maximum (Please see UTR2 in Fig. 4d). This indicates that glycolytic flux with UTR3 corresponds to the capacity of the engineered *n*-butanol synthesis pathway and glycolytic fluxes below this level can be regarded as the rate-limiting step for the production of *n*-butanol (Fig. 4d). The JHL179 strain with the UTR5 variant, whose rate of glucose uptake was higher (+18.34%) than that of the parental strain, showed substantial reductions in yield as well as productivity owing to a significant decrease in pH resulting from acidic pyruvate accumulation (+42.65% compared to UTR_{WT}; Fig. 4c), which negatively affected glucose consumption (Fig. 4b). Taken together, our results demonstrate that yield can be maximized while maintaining maximum productivity simply by optimizing the glycolytic flux according to the capacity of the product formation pathways via fine-control of *ptsG*.

Improvement in productivity by enhanced glycolytic activity through UTR engineering of *ptsG*

In general, product yield can be maximized via the deletion of pathways for unnecessary by-product formation, but increasing productivity beyond this maximized yield is challenging [7]. Nevertheless, further increases in productivity, while maintaining the maximum yield can be expected by enhancing the glycolytic flux if the capacity of the product formation pathway is higher than the natural glycolytic activity.

To verify this, previously engineered *E. coli* strains for the production of butyrate [4] and 2,3-butanediol [5] were exploited as model systems; their product yields were close to the theoretical maximum due to the


elimination of native by-product formation pathways, such as lactate and ethanol. Since butyrate is a fermentative product, energy for biosynthesis is mostly generated by the butyrate production pathway under anaerobic conditions, and the engineered strain JHL265 showed 83.4% of the theoretical maximum yield (Fig. 5a) [4]. However, the biological conversion rate of 2,3-butanediol from pyruvate could be maximized in the presence of oxygen and therefore a portion of the carbon source should be consumed to generate energy by conversion to carbon dioxide (Fig. 5b) [39].

To enhance glycolytic activity, *ptsG* expression was activated using UTR5 (resulting JHL266). As expected, the amplified glucose consumption rate translated to 7% higher productivity for butyrate (1.45 mmol butyrate L/h) than the parental strain, while the yield was maintained at approximately 83% of theoretical maximum (Fig. 5c). In the case of 2,3-butanediol production, the productivity of the strain with higher glycolytic activity (UTR5), resulting JHL268, could be improved by 12.45% compared to the parental strain JHL267 (2.38 mmol 2,3-butanediol L/h), while maintaining the parental maximum yield (approximately 60% of the theoretical maximum), as shown in Fig. 5d. Our results clearly show that the productivity of biological processes could be improved by amplifying glycolysis *per se* through UTR engineering of *ptsG*.

Discussion

Although the entire pathway from sugar uptake to product formation has to be well-balanced for optimal yield and productivity, research in metabolic engineering has focused on production pathways. Furthermore, controlling glycolytic flux remains a daunting task owing to incomplete knowledge of the mechanisms that regulate glycolysis [14]. While many process control techniques, such as carbon limited fed-batch cultivation, are the standard approaches to control overflow metabolism [40], our approach has the advantage of increasing robustness of biological production by optimizing glycolytic flux at the genetic level.

In this study, we demonstrated the physiological relevance of *ptsG* to overall glycolytic activity as the simple method for the control of metabolic input. As small RNA SgrS inherently represses the translation of *ptsG* mRNA by sequestering its ribosome binding site and RNaseE-dependent cleavage through a short base-pairing interaction [21, 22], the glucose transporter encoded by *ptsG* was modulated using synthetic 5'-UTRs for the fine-control of translation efficiency in addition to the deregulation of SgrS. Although the molecular study for the UTR engineering-mediated mitigation of SgrS regulation should be further investigated, our physiological



results successfully demonstrate the ability to control the glycolytic flux through *ptsG* as shown in Fig. 3. Moreover, the redesign of native UTR for allowed an increase in glycolytic flux by 20.8% compared to the wild type, even though none of the overexpressed glycolytic enzymes increased glycolytic activity in previous studies [41–43]. Since native glycolytic activity is often not sufficient for non-native product formation pathways and therefore increased glycolytic activity is necessary to maximize the rate of product formation for industrial applications, the observation that *ptsG* might be a preliminary rate-determining step in glycolysis is also intriguing.

Using these findings, the optimal glycolytic flux was explored with respect to the capacity of the *n*-butanol, butyrate, and 2,3-butanediol synthesis pathways to improve cellular performance. Interestingly, the yield

of *n*-butanol increased to 93% of the theoretical maximum due to a reduction in pyruvate secretion in accordance with tuning down of the glycolytic flux. Conversely, enhanced productivity was observed for the production of butyrate and 2,3-butanediol by activating the expression level of *ptsG* (via UTR5). Collectively, these results clearly indicate that optimization of the glycolytic flux enables additional improvements in both yield and productivity of cell factories, beyond optimization of the product formation pathway.

The concept of optimizing glycolytic flux is also important to the microbial production of various chemicals and fuels from cost-effective feedstock, such as glycerol [44] and galactose [45] and our strategy can be applied to explore optimal glycolytic flux depending on the capacity of product formation pathway via fine-control of glycerol

transporter (encoded by *glpF*) [46] and galactose transporter (encoded by *galP*) [47], respectively. Ultimately, as summarized in Fig. 6, balanced pathway amplification of both glycolytic flux and product-forming pathways are highly desirable for the design of economically feasible microbial cell factories in the bio-based chemical industry.

Conclusions

In this study, we examined the metabolic imbalance between glycolysis and product formation pathways using recombinant *Escherichia coli* strains producing *n*-butanol, butyrate, or 2,3-butanediol as model cell factories. Initially, the glucose uptake rate of wild-type *E. coli* was fine-tuned using synthetic UTRs of *ptsG* to modulate the overall glycolytic fluxes, which were assessed by physiological parameters, i.e., specific growth rate and the accumulation of acetate and pyruvate as natural by-products. Moving forward, glycolytic flux was rebalanced via the control of *ptsG* depending on the efficiency of product formation pathways with lower (*n*-butanol) and higher (butyrate and 2,3-butanediol) product formation capacities compared to the wild-type glycolytic flux. For the production of *n*-butanol, glycolytic flux successfully tuned down to minimize by-product formation,




Fig. 6 Plausible scenarios regarding the efficiencies of the two pathways: (i) Reduced yield and productivity ($\text{Flux}_{\text{Glycolysis}} > \text{Capacity}_{\text{Product-forming pathway}}$). (ii) Maximized yield, but reduced productivity due to glycolytic flux, which itself acts as a rate-limiting step ($\text{Flux}_{\text{Glycolysis}} < \text{Capacity}_{\text{Product-forming pathway}}$). Further improvement in productivity is restricted when the product-forming pathway exceeds the upper biological constraint ($\text{Flux}_{\text{Glycolysis, Max}} < \text{Capacity}_{\text{Product-forming pathway}}$). The faded region has never been explored. The red arrow indicates the optimized conditions for both glycolysis and the product-forming pathway (Balanced pathway, see “Discussion”)

while maintaining productivity, which we termed leak-free pathway engineering. Conversely, butyrate and 2,3-butanediol production rates were increased using a UTR variant of *ptsG* with higher glycolytic flux than that of the wild type. These results demonstrate the simple method to control glycolytic flux for the design of optimal cell factories in the fields of metabolic engineering and synthetic biology.

Additional file

Additional file 1. Additional figures, tables and reference.

Abbreviations

DCW: dry cell weight; OD: optical density; PEP: phosphoenolpyruvate; PTS: phosphotransferase system; TCA: tricarboxylic acid; UTR: untranslated region.

Authors' contributions

JHL and GYJ conceived of and designed the study, performed the experiments, analyzed the data, and wrote the manuscript. Both authors read and approved the final manuscript.

Author details

¹ Department of Chemical Engineering, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Korea. ² School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, 77 Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Korea.

Acknowledgements

We are grateful to Dr. Min-Kyu Oh (Korea University) for the generous gift of the plasmid pZSbudABC.

Competing interests

The authors declare that they have no competing interests.

Availability of supporting data

All data generated or analyzed during this study are included in this published article and its Additional information file.

Funding

This research was supported by grants from the Advanced Biomass R&D Center (ABC) of Global Frontier Project (ABC-2015M3A6A2066119) and C1 Gas Refinery Program (NRF-2016M3D3A1A01913237) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning, Korea.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 November 2016 Accepted: 13 June 2017

Published online: 21 June 2017

References

- Curran KA, Alper HS. Expanding the chemical palate of cells by combining systems biology and metabolic engineering. *Metab Eng*. 2012;14(4):289–97.
- Keasling JD. Manufacturing molecules through metabolic engineering. *Science*. 2010;330(6009):1355–8.

3. Lim JH, Seo SW, Kim SY, Jung GY. Model-driven rebalancing of the intracellular redox state for optimization of a heterologous *n*-butanol pathway in *Escherichia coli*. *Metab Eng*. 2013;20:49–55.
4. Lim JH, Seo SW, Kim SY, Jung GY. Refactoring redox cofactor regeneration for high-yield biocatalysis of glucose to butyric acid in *Escherichia coli*. *Bioresour Technol*. 2013;135:568–73.
5. Mazumdar S, Lee J, Oh MK. Microbial production of 2,3-butanediol from seaweed hydrolysate using metabolically engineered *Escherichia coli*. *Bioresour Technol*. 2013;136:329–36.
6. Wang BL, Ghaderi A, Zhou H, Agresti J, Weitz DA, Fink GR, et al. Microfluidic high-throughput culturing of single cells for selection based on extracellular metabolite production or consumption. *Nat Biotechnol*. 2014;32(5):473–8.
7. Van Dien S. From the first drop to the first truckload: commercialization of microbial processes for renewable chemicals. *Curr Opin Biotech*. 2013;24(6):1061–8.
8. Xu P, Ranganathan S, Fowler ZL, Maranas CD, Koffas MA. Genome-scale metabolic network modeling results in minimal interventions that cooperatively force carbon flux towards malonyl-CoA. *Metab Eng*. 2011;13(5):578–87.
9. Bogorad IW, Lin TS, Liao JC. Synthetic non-oxidative glycolysis enables complete carbon conservation. *Nature*. 2013;502(7473):693–7.
10. Farmer WR, Liao JC. Reduction of aerobic acetate production by *Escherichia coli*. *Appl Environ Microb*. 1997;63(8):3205–10.
11. Chang DE, Shin S, Rhee JS, Pan JG. Acetate metabolism in a *pta* mutant of *Escherichia coli* W3110: importance of maintaining acetyl coenzyme A flux for growth and survival. *J Bacteriol*. 1999;181(21):6656–63.
12. Xu P, Gu Q, Wang WY, Wong L, Bower AGW, Collins CH, et al. Modular optimization of multi-gene pathways for fatty acids production in *E. coli*. *Nat Commun*. 2013;4:1409.
13. Jones JA, Toparlak OD, Koffas MA. Metabolic pathway balancing and its role in the production of biofuels and chemicals. *Curr Opin Biotech*. 2015;33:52–9.
14. Wadler CS, Vanderpool CK. A dual function for a bacterial small RNA: SgrS performs base pairing-dependent regulation and encodes a functional polypeptide. *Proc Natl Acad Sci USA*. 2007;104(51):20454–9.
15. Bongaerts J, Kramer M, Muller U, Raeven L, Wubbolts M. Metabolic engineering for microbial production of aromatic amino acids and derived compounds. *Metab Eng*. 2001;3(4):289–300.
16. Berry A. Improving production of aromatic compounds in *Escherichia coli* by metabolic engineering. *Trends Biotechnol*. 1996;14(7):250–6.
17. Solomon KV, Sanders TM, Prather KLJ. A dynamic metabolite valve for the control of central carbon metabolism. *Metab Eng*. 2012;14(6):661–71.
18. Solomon KV, Moon TS, Ma B, Sanders TM, Prather KL. Tuning primary metabolism for heterologous pathway productivity. *ACS Synth Biol*. 2013;2(3):126–35.
19. Gosset G. Improvement of *Escherichia coli* production strains by modification of the phosphoenolpyruvate: sugar phosphotransferase system. *Microb Cell Fact*. 2005;4:14.
20. Deutscher J, Francke C, Postma PW. How phosphotransferase system-related protein phosphorylation regulates carbohydrate metabolism in bacteria. *Microbiol Mol Biol Rev*. 2006;70(4):939–1031.
21. Morita T, El-Kazzaz W, Tanaka Y, Inada T, Aiba H. Accumulation of glucose 6-phosphate or fructose 6-phosphate is responsible for destabilization of glucose transporter mRNA in *Escherichia coli*. *J Biol Chem*. 2003;278(18):15608–14.
22. Kimata K, Tanaka Y, Inada T, Aiba H. Expression of the glucose transporter gene, *ptsG*, is regulated at the mRNA degradation step in response to glycolytic flux in *Escherichia coli*. *EMBO J*. 2001;20(13):3587–95.
23. Morita T, Maki K, Aiba H. RNase E-based ribonucleoprotein complexes: mechanical basis of mRNA destabilization mediated by bacterial noncoding RNAs. *Genes Dev*. 2005;19(18):2176–86.
24. Vanderpool CK, Gottesman S. Involvement of a novel transcriptional activator and small RNA in post-transcriptional regulation of the glucose phosphoenolpyruvate phosphotransferase system. *Mol Microbiol*. 2004;54(4):1076–89.
25. Kawamoto H, Morita T, Shimizu A, Inada T, Aiba H. Implication of membrane localization of target mRNA in the action of a small RNA: mechanism of post-transcriptional regulation of glucose transporter in *Escherichia coli*. *Genes Dev*. 2005;19(3):328–38.
26. Maki K, Morita T, Otaka H, Aiba H. A minimal base-pairing region of a bacterial small RNA SgrS required for translational repression of *ptsG* mRNA. *Mol Microbiol*. 2010;76(3):782–92.
27. Seo SW, Yang J, Min BE, Jang S, Lim JH, Lim HG, et al. Synthetic biology: tools to design microbes for the production of chemicals and fuels. *Biotechnol Adv*. 2013;31(6):811–7.
28. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA*. 2000;97(12):6640–5.
29. Lim SI, Min BE, Jung GY. Lagging strand-biased initiation of Red recombination by linear double-stranded DNAs. *J Mol Biol*. 2008;384(5):1098–105.
30. Heermann R, Zeppenfeld T, Jung K. Simple generation of site-directed point mutations in the *Escherichia coli* chromosome using Red (R)/ET (R) recombination. *Microb Cell Fact*. 2008;7:14.
31. Seo SW, Yang JS, Kim I, Yang J, Min BE, Kim S, et al. Predictive design of mRNA translation initiation region to control prokaryotic translation efficiency. *Metab Eng*. 2013;15:67–74.
32. Negrete A, Ng WI, Shiloach J. Glucose uptake regulation in *E. coli* by the small RNA SgrS: comparative analysis of *E. coli* K-12 (JM109 and MG1655) and *E. coli* B (BL21). *Microb Cell Fact*. 2010;9:75.
33. Varma A, Palsson BO. Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type *Escherichia coli* W3110. *Appl Environ Microb*. 1994;60(10):3724–31.
34. Jung J, Lim JH, Kim SY, Im DK, Seok JY, Lee SV, et al. Precise precursor rebalancing for isoprenoids production by fine control of *gapA* expression in *Escherichia coli*. *Metab Eng*. 2016;38:401–8.
35. Kayser A, Weber J, Hecht V, Rinas U. Metabolic flux analysis of *Escherichia coli* in glucose-limited continuous culture. I. Growth-rate-dependent metabolic efficiency at steady state. *Microbiology*. 2005;151(Pt 3):693–706.
36. Wolfe AJ. The acetate switch. *Microbiol Mol Biol Rev*. 2005;69(1):12–50.
37. Shen CR, Lan EI, Dekishima Y, Baez A, Cho KM, Liao JC. Driving forces enable high-titer anaerobic 1-butanol synthesis in *Escherichia coli*. *Appl Environ Microb*. 2011;77(9):2905–15.
38. Nielsen DR, Leonard E, Yoon SH, Tseng HC, Yuan C, Prather KLJ. Engineering alternative butanol production platforms in heterologous bacteria. *Metab Eng*. 2009;11(4–5):262–73.
39. Ji XJ, Huang H, Ouyang PK. Microbial 2,3-butanediol production: a state-of-the-art review. *Biotechnol Adv*. 2011;29(3):351–64.
40. Eiteman MA, Altman E. Overcoming acetate in *Escherichia coli* recombinant protein fermentations. *Trends Biotechnol*. 2006;24(11):530–6.
41. Koebmann BJ, Westerhoff HV, Snoep JL, Nilsson D, Jensen PR. The glycolytic flux in *Escherichia coli* is controlled by the demand for ATP. *J Bacteriol*. 2002;184(14):3909–16.
42. Ruyter GJ, Postma PW, van Dam K. Control of glucose metabolism by enzyme II_{Glc} of the phosphoenolpyruvate-dependent phosphotransferase system in *Escherichia coli*. *J Bacteriol*. 1991;173(19):6184–91.
43. Jojima T, Inui M. Engineering the glycolytic pathway: a potential approach for improvement of biocatalyst performance. *Bioengineered*. 2015;6(6):328–34.
44. Lim HG, Noh MH, Jeong JH, Park S, Jung GY. Optimum rebalancing of the 3-hydroxypropionic acid production pathway from glycerol in *Escherichia coli*. *ACS Synth Biol*. 2016;5(11):1247–55.
45. Lim HG, Lim JH, Jung GY. Modular design of metabolic network for robust production of *n*-butanol from galactose-glucose mixtures. *Biotechnol Biofuels*. 2015;8:137.
46. Murarka A, Dharmadi Y, Yazdani SS, Gonzalez R. Fermentative utilization of glycerol by *Escherichia coli* and its implications for the production of fuels and chemicals. *Appl Environ Microbiol*. 2008;74(4):1124–35.
47. Lim HG, Seo SW, Jung GY. Engineered *Escherichia coli* for simultaneous utilization of galactose and glucose. *Bioresour Technol*. 2013;135:564–7.
48. Kawamoto H, Koide Y, Morita T, Aiba H. Base-pairing requirement for RNA silencing by a bacterial small RNA and acceleration of duplex formation by Hfq. *Mol Microbiol*. 2006;61(4):1013–22.